For research use only. Not for therapeutic Use.
VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinases 1 (VRK1), with an IC50 of 150 nM. VRK1 is human Ser/Thr protein kinases associated with increased cell division and neurological disorders[1].
VRK-IN-1 binds to VRK1-FL by enthalpy-driven, with a Kd of 190 nM[1].?
VRK-IN-1 (0.4-25 μM; 24 h) slightly decreases the viability of human HeLa cells at the concentration of 3.2 μM[1].
| Catalog Number | I044339 |
| CAS Number | 2378855-09-3 |
| Synonyms | 4-[5-(3,5-difluoro-4-hydroxyphenyl)-6-methylpyridin-3-yl]-2,6-difluorophenol |
| Molecular Formula | C18H11F4NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H11F4NO2/c1-8-12(10-5-15(21)18(25)16(22)6-10)2-11(7-23-8)9-3-13(19)17(24)14(20)4-9/h2-7,24-25H,1H3 |
| InChIKey | PMRGRXLXKYUDIH-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=N1)C2=CC(=C(C(=C2)F)O)F)C3=CC(=C(C(=C3)F)O)F |
| Reference | [1]. Serafim RAM, et, al. Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2. ACS Med Chem Lett. 2019 Aug 19;10(9):1266-1271. |
